The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma

Blood

Volumn 93, Issue 10, 1999, Pages 3487-3493

  Jones, Dan ^b   Fletcher, Christopher D M ^b   Pulford, Karen ^b   Shahsafaei, Aliakbar ^b   Dorfman, David M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE SURFACE MARKER; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TUMOR BIOPSY; TUMOR CLASSIFICATION;

EID: 0033562603     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.10.3487.410k39_3487_3493     Document Type: Article

References (53)

1. Ryffel B, Vrockhaus M, Durmuller U, Gudat F: Tumor necrosis factor receptors in lymphoid tissues and lymphomas. Source and site of action of tumor necrosis factor alpha. Am J Pathol 139:7, 1991
2. Kondo E, Yoshino T, Yamadon I, Matsuo Y, Kawasaki N, Minowada J, Akagi T: Expression of bcl-2 protein and fas antigen in non-Hodgkin's lymphoma. Am J Pathol 145:330, 1994
3. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein M, Henne C, Schmidt A, Debatin K-M, Krammer PH, Moller P: Consitutive and induced expression of APO-1: A new member of the nerve growth factor/tumor necrosis factor receptor superfamily in normal and neoplastic cells. Lab Invest 69:415, 1993
4. Nguyen PL, Harris NL, Ritz J, Robertson MJ: Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 148:847, 1996 (erratum 149:346, 1996)
5. Xerri L, Carbuccia N, Parc P, Hassoun J, Birg F: Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology 27:235, 1995
6. Gruss HJ, Hermann F, Gattei V, Gloghini A, Pinto A, Carbone A: CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 24:393, 1997
7. al-Shamkhani A, Birkeland ML, Puklavec M, Brown MH, James W, Barclay AN: OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol 26:1695, 1996
8. Durkop H, Latza U, Himmelreich P, Stein H: Expression of the human OX40 (hOX40) antigen in normal and neoplastic tissues. Br J Haematol 91:927, 1995
9. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, DeWolf-Peeters C, Falini B, Gatter KC, Grogan TM, Issacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-America Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
10. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe M-J, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G: ALK-positive lymphoma: A single disease with abroad spectrum of morphology. Blood 91:2076, 1998
11. Jones D, Jorgensen JL, Shahsafaei A, Dorfman DM: Characteristic reticular and dendritic proliferations in angioimmunoblastic lymphoma. Am J Surg Pathol 22:956, 1998
12. Dorfman DM, Shahsafaei A: Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas. Mod Pathol 9:959, 1996
13. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, Mason DY: Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89:1394, 1997
14. Herbst H, Anagnostopoulos J, Heinze B, Durkop H, Hummel M, Stein H: ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease. Blood 86:1694, 1995
15. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F: Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89:4514, 1997
16. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mon N, Fujimoto J, Miyauchi J, Mikata A, Nanbo K, Takami T, Yamabe H, Takano Y, Izumo T, Mohri N, Nasu K, Satoh H, Katano H, Fujimoto J, Yamamoto T, Mon S: Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 86:1954, 1995
17. Nakamura S, Shiota M, Nakagawa A, Yatabe Y, Kojima M, Motoori T, Suzuki R, Kagami Y, Ogura M, Morishima Y, Mizoguchi Y, Okamoto M, Seto M, Koshikawa T, Mori S, Suchi T: Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 21:1420, 1997
18. + primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Blood 88:1765, 1996
19. Kummer JA, Vermeer MH, Dukers D, Meijer CJ, Willemze R: Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 109:636, 1997
20. Krenacs L, Wellmann A, Sorbara L, Himmelmann AW, Bagdi E, Jaffe ES, Raffeld M: Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T-and null-cell type and Hodgkin's disease: Evidence for distinct cellular origin. Blood 89:980, 1997
21. Foss HD, Anagnostopoulos I, Araujo I, Assaf C, Demel G, Kummer JA, Hummel M, Stein H: Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 88:4005, 1996
22. Mallett S, Fossum S, Barclay AN: Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - A molecule related to nerve growth factor receptor. EMBO J 9:1063, 1990
23. Calderhead DM, Buhlmann JE, van den Eertwegh AJ, Claassen E, Noelle RJ, Fell HP: Cloning of mouse OX40: A T cell activation marker that may mediate T-B cell interactions, J Immunol 151:5261, 1993
24. Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T: Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2-and TRAF5-mediated NF-kappaB activation. J Biol Chem 273:5808, 1998
25. Arch RH, Thompson CB: 4-1BB and OX40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 18:558, 1998
26. Baum PR, Gayle RBd, Ramsdell F, Srinivasan S, Sorensen RA, Watson ML, Seldin MF, Clifford KN, Grabstein K, Alderson MR, Goodwin RG, Fenslow WC: Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor. Circ Shock 44:30, 1994
27. Flynn S, Toellner KM, Raykundalia C, Goodall M, Lane P: CD4 T cell cytokine differentiation: The B cell activation molecule, 0X40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 188:297, 1998
28. Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG: Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med 180:757, 1994
29. Stuber E, Strober W: The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 183:979, 1996
30. Imura A, Hori T, Imada K, Kawamata S, Tanaka Y, Imamura S, Uchiyama T: OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: Implication for the possible involvement of OX40 in leukemic cell infiltration. Blood 89:2951, 1997
31. Schlegelberger B, Feller A, Godde E, Grote W, Lennert K: Stepwise development of chromosomal abnormalities in angioimmunoblastic lymphadenopathy. Cancer Genet Cytogenet 50:15, 1990
32. Kaneko Y, Maseki N, Sakurai M, Takayama S, Nanba K, Kikuchi M, Frizzera G: Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive "angioimmunoblastic lymphadenopathy with dysproteinemia-type" features. Blood 72:413, 1988
33. Uchiyama T: ATL and HTLV-I: In vivo cell growth of ATL cells. J Clin Immunol 16:305, 1996
34. Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, Imamura S, Uchiyama T: The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 183:2185, 1996
35. Matsumura Y, Imura A, Hori T, Uchiyama T, Imamura S: Localization of OX40/gp34 in inflammatory skin diseases: A clue to elucidate the interaction between activated T cells and endothelial cells in infiltration. Arch Dermatol Res 289:653, 1997
36. Takeshita M, Akamatsu M, Ohshima K, Kobari S, Kikuchi M, Suzumiya J, Uike N, Okamura T: CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathology 26:539, 1995
37. Penny RJ, Blaustein JC, Longtine JA, Pinkus GS: Ki-1 positive large cell lymphomas, a heterogeneous group of neoplasms. Cancer 68:362, 1991
38. Piris M, Brown DC, Gatter KC, Mason DY: CD30 expression in non-Hodgkin's lymphoma. Histopathology 17:211, 1990
39. Miettinen M: CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas. Arch Pathol Lab Med 116:1197, 1992
40. Chott A, Kaserer K, Augustin I, Vesely M, Heinz R, Oehlinger W, Hanak H, Radaszkiewicz T: Ki-1-positive large cell lymphoma. Am J Surg Pathol 14:439, 1990
41. Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, Aldinucci D, Perin V, Serraino D, Babare R, Zagonel V, Gruss HJ, Carbone A, Pinto A: CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 89:2048, 1997
42. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 383:787, 1996
43. Del Prete G, Maggi E, Pizzolo G, Romagnani S: CD30, Th2 cytokines and HIV infection: A complex and fascinating link. Immunol Today 16:76, 1995
44. Hamann D, Hilkens CM, Grogan JL, Lens SM, Kapsenberg ML, Yazdanbakhsh M, van Lier RA: CD30 expression does not discriminate between human Th1-and Th2-type T cells. J Immunol 156:1387, 1996
45. D'Elios MM, Romagnani P, Scaletti C, Annunziato F, Manghetti M, Mavilia C, Parronchi P, Pupilli C, Pizzolo G, Maggi E, Prete GFD: In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol 61:539, 1997
46. Gilfillan MC, Noel PJ, Podack ER, Reiner S, Thompson CB: Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 160:2180, 1998
47. Vetto JT, Lum S, Morris A, Sicotte M, Davis J, Lemon M, Weinberg A: Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg 174:258, 1997
48. Ohshima Y, Yang LP, Uchiyama T, Tanaka Y, Baum P, Sergerie M, Hermann P, Delespesse G: OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 92:3338, 1998
49. Roos A, Schilder-Tol EJ, Weening JJ, Aten J: Strong expression of CD134 (OX40), a member of the TNF receptor family, in a T helper 2-type cytokine environment. J Leukoc Biol 64:503, 1998
50. Bonecchi R, Bianchi G, Bordignon PP, D' Ambnrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F: Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187:129, 1998
51. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer J-M: CCR5 is characteristic of Th1 lymphocytes. Nature 391:344, 1998
52. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AR, Oser BM, Mackay CR: The chemokine receptors CXCR3 and CCR mark subsets of T ceels associated with certain inflammatory reactions. J Clin Invest 101:746, 1998
53. Sallusto F, Mackay CR, Lanzavecchia A: Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277:2005, 1997